Derivation of utility values from EORTC QLQC30 in lung cancer

被引：2
|
作者：
Jang, R. W.
Mittmann, N. [2 ]
Isogai, P. [2 ]
Bradbury, P. A. [1 ]
Leighl, N. B.
机构：
[1] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
[2] HOPE Res Ctr, Toronto, ON, Canada
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70254-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A77 / A78
页数：2
相关论文
共 50 条
  • [31] Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma-Interpretation guidance derived from two randomized EORTC trials
    Koller, Michael
    Musoro, Jammbe Z.
    Tomaszewski, Krzysztof
    Coens, Corneel
    King, Madeleine T.
    Sprangers, Mirjam A. G.
    Groenvold, Mogens
    Cocks, Kim
    Velikova, Galina
    Flechtner, Hans-Henning
    Bottomley, Andrew
    LUNG CANCER, 2022, 167 : 65 - 72
  • [32] NAVIGATING INDIRECT UTILITY MODELS IN CANCER: MAPPING THE EORTC QLQ-C30 ONTO THE EQ-5D
    Doble, Brett
    Harris, Anthony
    Lorgelly, Paula
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 121 - 121
  • [33] Applying utility values in cost-effectiveness analyses of lung cancer screening: A review of methods
    Ngo, Preston J.
    Cressman, Sonya
    Behar-Harpaz, Silvia
    Karikios, Deme J.
    Canfell, Karen
    Weber, Marianne F.
    LUNG CANCER, 2022, 166 : 122 - 131
  • [34] HEALTH STATE UTILITY VALUES IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
    Chevalier, J.
    Le Lay, K.
    de Pouvourville, G.
    VALUE IN HEALTH, 2013, 16 (07) : A419 - A419
  • [35] Definition of Resectable Stage III Non-Small Cell Lung Cancer: A Systematic Review from EORTC Lung Cancer Group
    Xenophontos, E.
    Levra, N. Giaj
    Durieux, V.
    Van Geffen, W.
    Grisay, G.
    De la Pinta Alonso, C.
    Arasanz Esteban, H.
    Prisciandaro, E.
    Ferrara, R.
    Derks, J.
    Von der Thusen, J.
    Dickhoff, C.
    Brandao, M.
    Faivre-Finn, C.
    Edwards, J.
    De Ruysscher, D.
    Remon, J.
    Dingemans, A. -M.
    Berghmans, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S292 - S292
  • [36] Assessing utility values for oral cancer and precancer from the general public.
    Jullien, JA
    Speight, PM
    Downer, MC
    JOURNAL OF DENTAL RESEARCH, 1996, 75 (05) : 1163 - 1163
  • [37] DERIVATION OF UTILITY VALUES FOR PATIENTS WITH ADVANCED HEPATOCELULAR CARCINOMA BASED ON HRQOL DATA FROM THE PHASE 3 CELESTIAL TRIAL
    Mollon, P.
    Freemantle, N.
    Benzaghou, F.
    Valcheva, V.
    Guerra, I
    McKaig, S.
    Roset, M.
    Sanchez, E.
    VALUE IN HEALTH, 2019, 22 : S112 - S112
  • [38] EORTC QLQ-C30 and EORTC QLQ-PR25 - tools for assessing the quality of life of men suffering from prostate cancer
    Jurys, Tomasz
    Smolka, Mikolaj
    Dzierzawa-Kloza, Monika
    Stepanik, Michalina
    Burzynski, Bartlomiej
    ONCOLOGY IN CLINICAL PRACTICE, 2022, 18 (01): : 61 - 67
  • [39] A non-linear beta-binomial regression model for mapping qlqc-30 to the eq-5d in lung cancer patients: a comparison with existing approaches
    Iftekhar Khan
    Shah-Jalal Sarker
    Steven Morris
    Trials, 14 (Suppl 1)
  • [40] Investigation of quality of life in patients with lung cancer by the EORTC QLQ-C30(V3.0) Chinese version
    Jun Li
    Xiaoguang Xiao
    Yao Wei
    Yang Li
    Man Zou
    Shiying Yu
    Yuan Chen
    Qian Chu
    OncologyandTranslationalMedicine, 2015, 1 (03) : 125 - 129
12345